Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 30 OCTOBER 2017

Top 10 Practice Points By Experts: Foreign Private Issuers

Milbank
Milbank
Contributor
Milbank

Milbank

Milbank has been in London for over 40 years, assisting clients with their most complex,...

View firm profile
Explore more from Milbank

Foreign Private Issuers, or FPIs, require a significant amount of guidance from experienced outside counsel.

United StatesCorporate/Commercial Law
Marcelo Mottesi
Marcelo Mottesi
Author LinkedIn connections

Foreign Private Issuers, or FPIs, require a significant amount of guidance from experienced outside counsel. FPIs can benefit from the status and increased visibility that comes with being a Securities and Exchange Commission (SEC) registered company, while enjoying accommodations with respect to U.S. securities laws and stock exchange regulations not available to U.S. domestic public companies. However, FPIs need to be cognizant of the regulatory landscape applicable to them, which still imposes certain costs and burdens. Below are 10 practice tips that can help you handle foreign private issuers without panicking.

1. DISCUSS AND ASSIST WITH ONGOING REPORTING OBLIGATIONS

FPIs are required to comply with three major disclosure requirements:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP
Article

SEC Proposes Amendments To Permit Optional Semiannual Reporting By Public Companies

The U.S. Securities and Exchange Commission has proposed rule amendments that would allow public companies to choose semiannual reporting instead of quarterly reports for their periodic reporting obligations. This potential shift in the regulatory framework aims to reduce compliance burdens while maintaining investor protections, giving companies flexibility to determine the reporting frequency that best serves their stakeholders.
United StatesCorporate/Commercial Law
Milbank
Milbank